{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-026760","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2022-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.219876+00:00","generated_at":"2026-06-23T07:27:31.594088+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulmatrix completes dosing in Phase 1 trial of inhaled PUR3100 for acute migraine; data expected Q4 2022","bullets":["All 26 healthy subjects completed dosing in double-blind, double-dummy Phase 1 trial of PUR3100 (inhaled DHE) vs IV DHE.","Phase 1 safety, tolerability, and PK data expected in Q4 2022.","PUR3100 uses iSPERSE dry-powder technology for self-administered inhaled delivery of dihydroergotamine.","Migraine affects 38M in U.S.; 75% do not get relief from current prescription treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-026760","json":"https://secwatch.observer/filing/0001493152-22-026760.json","markdown":"https://secwatch.observer/filing/0001493152-22-026760.md","text":"https://secwatch.observer/filing/0001493152-22-026760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222026760/0001493152-22-026760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222026760/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:27:31.594088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}